NEW YORK (GenomeWeb News) – Cancer Genetics again lowered the amount it expects to raise in its pending initial public offering.

In a Form S-1/A filed with the US Securities and Exchange Commission on Monday, the Rutherford, NJ-based firm said that it expects to offer 1.85 million shares of stock in its IPO at a price of between $10 and $12 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.